CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Phase 1 Recruiting
120 enrolled
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
Phase 1 Completed
48 enrolled 13 charts
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
Phase 1 Terminated
13 enrolled
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Completed
23 enrolled
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
Phase 1 Withdrawn
AML1208
Phase 1 Completed
11 enrolled
Brentuximab Vedotin + Re-induction Chemotherapy for AML
Phase 1 Completed
22 enrolled
Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
Phase 1 Completed
25 enrolled
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias
Phase 1 Terminated
22 enrolled
UPCC 02407
Phase 1 Completed
16 enrolled
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
Phase 1 Terminated
2 enrolled
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Completed
30 enrolled
Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone
Phase 1 Completed
42 enrolled
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Terminated
17 enrolled
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Completed
67 enrolled
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
Phase 1 Terminated
10 enrolled
Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia
Phase 1 Completed
29 enrolled
Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia
Phase 1 Terminated
1 enrolled
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
Phase 1 Completed
25 enrolled
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
Phase 1 Terminated
5 enrolled
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Completed
3 enrolled
AML
Phase 1 Terminated
6 enrolled
Vandevol
Phase 1 Completed
20 enrolled
Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Phase 1 Completed
7 enrolled
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
Phase 1 Completed
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer
Phase 1 Completed